Pricing Sign in

FULC

Fulcrum Therapeuticsdistress 6/10 · elevated risk

$3.64-2%today-75% from 52w high

fulcrumtx.com55 employeesFounded 2015Cambridge, MABiotechnology

Rare / Genetic 2

Lead: sickle cell disease · est. market ~$5B (approx, global)

Revenue

pre-revenue

Liquidity

$50M

Runway

0.8 yrs

Shares 1y

+23%

Price & events

-67.1% over 6M

CatalystRating changeDilutionFinancingdashed = today

-1.6%

1D

+4.0%

1W

-5.5%

1M

-55.0%

3M

-66.1%

6M

-54.0%

1Y

-58.8%

2Y

-54.5%

5Y

-70.7%

All

Overview

Market Cap: $242.55M
Volume: 162.89K
52 Week Range: $3.14 – $14.60
Total Shares: 66.63M
Float Shares: 41.99M
Short %: 9.76%
% Held by Insiders: 3.83%
% Held by Institutions: 126.06%
RVOL: 0.06x
Beta: 3.00

Pipeline stages · 1 programs

Pociredir

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2030-02-04

Pipeline · 3 trials · 1 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2030-02-04 Estimated 50% readout ~2030-03-21	Phase 2	Pociredirfast trackorphan	Sickle Cell Disease	—	enrolling by invitation
2026-06-01	Phase 1	Pociredirfast trackorphan	Sickle Cell Disease	13	terminated
2026-01-20	Phase 1	Pociredir oral capsule(s)fast trackorphan	Sickle Cell Disease, Sickle Cell Anemia	45	completed

Catalyst news & presentations · 12

2H 2026Guided 55%trial initiationsecondarypociredir · Next study initiationSEC 8-K
2026-07-29earningsEarningsEarnings releaseyahoo
second quarter of 2026regulatory submissionFiled (NDA/BLA)pociredir · IND submission for bone marrow failure syndromesSEC 8-K
2026-06-01trial discontinuedpociredir · Discontinued due to FDA concerns about malignancy risk from PRC2 inhibitionSEC 8-K
Q1 2026readoutPhase 1pociredir · Updated results from 20 mg cohort of Phase 1b PIONEER trialSEC 8-K
YE 2025enrollment completesecondaryPhase 1pociredir · Enrollment completion of Cohort 4 (20 mg) in PIONEER trial.SEC 8-K
Q4 2025regulatory submissionFiled (NDA/BLA)IND submission planned for novel HbF inducer in DBA and BMFS.SEC 8-K
Q4 2025regulatory submissionFiled (NDA/BLA)IND submission for discovery programsSEC 8-K
during the fourth quarter of 2025regulatory submissionFiled (NDA/BLA)IND submission for DBA programSEC 8-K
year-end 2025conferencedata presentationsecondaryPhase 1pociredir · Cohort 4 (20 mg) data disclosureSEC 8-K
October 1-4, 2025conferencedata presentationsecondaryReal-world data analysis on HbF levels and VOC accepted for publication at ASCATSEC 8-K
mid-2025conferencedata presentationsecondaryPhase 1pociredir · Cohort 3 (12 mg) data disclosureSEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 66,633,321 · 3 offerings/1y · 0 PIPEs

2025-12-118-Kmaterial_agreement
2025-12-11424B5offering
2025-12-10FWPoffering
2025-12-08424B5offering
2024-12-06SC 13Gstrategic_stake
2024-11-14SC 13G/Astrategic_stake
2024-11-14SC 13G/Astrategic_stake

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Wall St ratings

hold · target $6 (+60% upside) · 6 analysts

2026-06-03JP MorganOverweight → Underweight
2026-06-02Truist SecuritiesBuy → Hold
2026-06-02StifelBuy → Hold
2026-06-02Piper SandlerOverweight → Underweight
2026-06-02HC Wainwright & Co.Buy → Neutral
2026-06-02Leerink PartnersOutperform → Market Perform

Competitors — sickle cell disease

NVSEFNOVARTIS AG$292.0B · D3
PFEPFIZER INC$142.2B · D3
VRTXVERTEX PHARMACEUTICALS INC / MA$119.1B · D1
SNYSanofi$52.5B · D1
BEAMBeam Therapeutics Inc.$2.7B · D0
AGIOAGIOS PHARMACEUTICALS, INC.$2.1B · D5
EDITEditas Medicine, Inc.$266M · D6
SGMOSANGAMO THERAPEUTICS, INC$31M · D7
NONOFNOVO NORDISK A S— · D2
NVONOVO NORDISK A S— · D2

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.